Treatment with a Novel Chemokine-Binding Protein or Eosinophil Lineage-Ablation Protects Mice from Experimental Colitis
- 1 December 2009
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (6) , 2382-2391
- https://doi.org/10.2353/ajpath.2009.090093
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- The Unexpected Pleiotropic Activities of RANTESThe Journal of Immunology, 2009
- Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivoBMC Immunology, 2009
- Intestinal Macrophage/Epithelial Cell-Derived CCL11/Eotaxin-1 Mediates Eosinophil Recruitment and Function in Pediatric Ulcerative ColitisThe Journal of Immunology, 2008
- Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defenseNature Medicine, 2008
- Ticks produce highly selective chemokine binding proteins with antiinflammatory activityThe Journal of Experimental Medicine, 2008
- THE EOSINOPHILAnnual Review of Immunology, 2006
- Comparison of RANTES expression in Crohn’s disease and ulcerative colitis: an aid in the differential diagnosis?Journal of Clinical Pathology, 2006
- Differential expression of chemokines and chemokine receptors in inflammatory periapical diseasesOral Microbiology and Immunology, 2005
- Increased Intraluminal Release of Eosinophil Granule Proteins Epo, Ecp, Epx, and Cytokines in Ulcerative Colitis and Proctitis in Segmental PerfusionAmerican Journal of Gastroenterology, 1999
- Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritisInternational Immunology, 1999